Literature DB >> 6891625

Pharmacokinetic modeling of cisplatin disposition in children and adolescents with cancer.

W E Evans, W R Crom, A Tsiatis, A A Green, F A Hayes, C B Pratt.   

Abstract

A flow-limited physiologic pharmacokinetic model using volume terms, flow rates, distribution ratios, metabolic rate constants, and clearance terms restricted to physiologic or measured values was used to simulate the disposition of cisplatin in children and adolescents. Physiologic model simulations of parent cisplatin and total platinum serum concentrations were not statistically different from concentrations of these platinum species measured in 14 patients. A simplified first-order multicompartment operational model was also developed, and produced comparable simulations of parent cisplatin disposition but less accurate simulations of total platinum serum concentrations. These data provide further clarification of cisplatin disposition in humans and provide the basis for previously observed changes in the renal clearance of total platinum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6891625     DOI: 10.1007/bf00257231

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy.

Authors:  K B Bischoff
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

3.  Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man.

Authors:  H S Smith; D M Taylor
Journal:  J Nucl Med       Date:  1974-05       Impact factor: 10.057

4.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

5.  Platinum concentrations in bile and plasma following rapid and 6-hour infusions of cis-dichlorodiammineplatinum(II).

Authors:  E S Casper; D P Kelsen; N W Alcock; C W Young
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

6.  Measurement of free-circulating cis-dichlorodiammineplatinum(II) in plasma.

Authors:  S J Bannister; L A Sternson; A J Repta; G W James
Journal:  Clin Chem       Date:  1977-12       Impact factor: 8.327

Review 7.  Cisplatin (cis-diamminedichloroplatinum II).

Authors:  A W Prestayko; J C D'Aoust; B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-03       Impact factor: 12.111

8.  Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.

Authors:  C B Pratt; A Hayes; A A Green; W E Evans; N Senzer; C B Howarth; J L Ransom; W Crom
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

9.  Cisplatin disposition in children and adolescents with cancer.

Authors:  W R Crom; W E Evans; C B Pratt; N Senzer; M Denison; A A Green; F A Hayes; G C Yee
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

10.  Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.

Authors:  A F LeRoy; R J Lutz; R L Dedrick; C L Litterst; A M Guarino
Journal:  Cancer Treat Rep       Date:  1979-01
  10 in total
  8 in total

Review 1.  Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Authors:  Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

2.  A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.

Authors:  P A Reece; I Stafford; J Russell; M Khan; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

Authors:  Hoai-Thu Thai; Florent Mazuir; Sylvaine Cartot-Cotton; Christine Veyrat-Follet
Journal:  Br J Clin Pharmacol       Date:  2015-08-14       Impact factor: 4.335

4.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

5.  Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.

Authors:  Susan F Hudachek; Daniel L Gustafson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-25       Impact factor: 2.745

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.

Authors:  Susan F Hudachek; Daniel L Gustafson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-12       Impact factor: 2.745

8.  A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin.

Authors:  H Griffiths; M D Shelley; R G Fish
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.